is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health’s business.

I am pleased to announce that Sotera Health delivered another year of top-line growth in 2024,” said Mr. Petras. “We expect full-year revenues will be approximately $1.1 billion, representing growth ...

A live webcast of Mr. Petras’ presentation and accompanying materials may be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health. A replay of ...

CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ ... Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

Reported $2.2 billion in preliminary*full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled ...

SAN FRANCISCO (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor ...

Paychex, Inc. (Nasdaq: PAYX) (“Paychex”), an industry-leading human capital management (HCM) company delivering a full suite of technology and advisor ...

J.P. Morgan Asset Management found stocks that initiated ... Beverage giant PepsiCo (NASDAQ:PEP) is the first Dividend King to buy for 2025. Its stock has been largely flat for the past few ...

The economic cost of the fires in Los Angeles has yet to be tabulated but changes are already happening in the markets ...

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reachin ...

Trump has to deliver on those promises, and Trump’s voters won’t be the only ones watching for those policies. Wall Street is ...